Balcoltra generic
Balcoltra is an oral contraceptive drug owned by Avion Pharmaceuticals. It is composed of Ethinyl Estradiol and Levonorgestrel. The drug was authorized for market use on January 9, 2018.
When will Balcoltra generic be available?
As of now, Balcoltra holds one patent which is due to expire on June 1, 2027. This patent, under the designation US7838042 pertains to hypoallergenic metal amino acid chelates contained in the drug. Therefore, the generic version of the Balcoltra could possibly be released after the patent expiration.
Balcoltra uses
Balcoltra is primarily used as a form of birth control. It contains Ethinyl Estradiol and Levonorgestrel, hormones that prevent ovulation (the release of an egg from an ovary) and cause changes in the cervical mucus and uterine lining, making it harder for a fertilized egg to attach to the uterus.
Balcoltra patent expiration
Balcoltra has one active patent, US7838042, which will expire on June 1, 2027. This patent focuses on its key component - hypoallergenic metal amino acid chelates. Therefore, the development of Balcoltra generic could happen after this date. Below are the details of the patent: